Drug Profile


Alternative Names: AB-0024; Anti-LOXL2 monoclonal antibody; GS-6624

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Arresto Biosciences
  • Developer Gilead Sciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Chemokine CXCL12 inhibitors; Connective tissue growth factor inhibitors; LOXL2 protein-inhibitors; Transforming growth factor beta1 inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatic fibrosis; Liver cirrhosis; Non-alcoholic steatohepatitis; Primary sclerosing cholangitis
  • Discontinued Colorectal cancer; Idiopathic pulmonary fibrosis; Myelofibrosis; Pancreatic cancer

Most Recent Events

  • 01 Aug 2016 Gilead Sciences completes a phase II trial for Primary sclerosing cholangitis in USA, Belgium, Canada, Denmark, Germany, Italy, Netherlands, Spain, Sweden and United Kingdom (SC) (NCT01672853)
  • 24 Feb 2016 Gilead Sciences terminates phase II trial in Idiopathic pulmonary fibrosis in USA (NCT01759511)
  • 05 Jan 2016 Discontinued - Phase-II for Idiopathic pulmonary fibrosis in United Kingdom, USA, Belgium, Czech Republic, Canada, Germany, Spain, Australia, Italy, South Korea, Poland, France, Israel, Switzerland (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top